Associated Papers
The GigaAssay: A combined high throughput and highly accurate platform for variant classification.
Giacoletto CJ et al.
New Biotechnology, 2025
High-throughput characterization of 5886 HER2 variants identifies 112 new in cellulo gain-of-function mutations.
Giacoletto CJ et al.
Genomics, 2025
New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation.
Giacoletto CJ et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S et al.
Breast Cancer Research : Bcr, 2020
Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
31034466 (PubMed )
Supplement: pcbi.1006981.s010.xlsx › final_benchmark
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F et al.
Breast Cancer Research and Treatment, 2017
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Bose R et al.
Cancer Discovery, 2013
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Lee JW et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
Select a paper to view details